Armata Pharmaceuticals Operating Margin 2006-2021 | ARMP

Current and historical operating margin for Armata Pharmaceuticals (ARMP) over the last 10 years. The current operating profit margin for Armata Pharmaceuticals as of September 30, 2021 is -594.94%.
Armata Pharmaceuticals Operating Margin Historical Data
Date TTM Revenue TTM Operating Income Operating Margin
2021-09-30 $0.00B $-0.02B -575.00%
2021-06-30 $0.00B $-0.02B -766.67%
2021-03-31 $0.00B $-0.02B -1100.00%
2017-12-31 $0.00B $-0.02B inf%
2017-09-30 $0.00B $-0.03B inf%
2017-06-30 $0.00B $-0.03B inf%
2017-03-31 $0.00B $-0.02B inf%
2016-12-31 $0.00B $-0.02B inf%
2016-09-30 $0.00B $-0.02B inf%
2016-06-30 $0.00B $-0.01B inf%
2016-03-31 $0.00B $-0.01B inf%
2015-12-31 $0.00B $-0.01B inf%
2015-09-30 $0.00B $-0.01B inf%
2015-06-30 $0.00B $-0.01B inf%
2015-03-31 $0.00B $-0.01B inf%
2014-12-31 $0.00B $-0.02B inf%
2014-09-30 $0.00B $-0.02B inf%
2014-06-30 $0.00B $-0.01B inf%
2014-03-31 $0.00B $-0.02B inf%
2013-12-31 $0.00B $-0.01B inf%
2013-06-30 $0.00B $-0.01B -166.67%
2013-03-31 $0.01B $0.00B 28.57%
2009-12-31 $0.01B $0.00B 16.67%
2009-09-30 $0.01B $-0.00B -27.27%
2009-06-30 $0.01B $-0.01B -77.78%
2009-03-31 $0.01B $-0.01B -137.50%
2008-12-31 $0.01B $-0.01B -162.50%
2008-09-30 $0.01B $-0.01B -155.56%
2008-06-30 $0.01B $-0.01B -155.56%
2008-03-31 $0.01B $-0.01B -140.00%
2007-12-31 $0.01B $-0.02B -150.00%
2007-09-30 $0.01B $-0.01B -118.18%
2007-06-30 $0.01B $-0.01B -118.18%
2007-03-31 $0.01B $-0.01B -144.44%
2006-12-31 $0.01B $-0.01B -133.33%
2006-09-30 $0.01B $-0.01B -200.00%
2006-06-30 $0.01B $-0.02B -266.67%
2006-03-31 $0.01B $-0.02B -283.33%
2005-12-31 $0.01B $-0.02B -300.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.141B $0.001B
Armata Pharmaceuticals Inc. is a biotechnology company. It is focused on the development of bacteriophage therapeutics for antibiotic-resistant infections using its proprietary bacteriophage-based technology. The company's principal product candidate consist AP-SA01, targets Staphylococcus aureus including multidrug-resistant strains. It is also developing and advancing a pipeline of synthetic phage candidates, including a synthetic phage for Pseudomonas aeruginosa. Armata Pharmaceuticals Inc., formerly known as AmpliPhi Biosciences Corporation, is based in Marina del Rey, California.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $125.477B 7.93
Bio-Rad Laboratories (BIO.B) United States $23.034B 46.74
QIAGEN (QGEN) Netherlands $12.874B 21.80
Biohaven Pharmaceutical Holding (BHVN) United States $7.457B 0.00
Arcus Biosciences (RCUS) United States $3.257B 0.00
Emergent Biosolutions (EBS) United States $2.378B 8.55
Myovant Sciences (MYOV) United Kingdom $1.780B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.529B 0.00
Zymeworks (ZYME) Canada $0.908B 0.00
Ambrx Biopharma (AMAM) United States $0.407B 0.00
SQZ Biotechnologies (SQZ) United States $0.345B 0.00
Enzo Biochem (ENZ) United States $0.164B 16.09